EGFR antibodies, such as cetuximab, demonstrate superior clinical efficacy in colorectal cancer (CRC) compared to EGFR-TKIs, which are primarily used in non-small cell lung cancer (NSCLC) with activating EGFR kinase domain mutations. Here, EGFR is linked to colorectal cancer.